$68.11 +0.05 (%) AbbVie Inc - NYSE

Nov. 26, 2014 | 11:00 AM

Partner Headlines

  1. Six High-Yielding Mega-Cap Stocks

    GuruFocus | Nov. 25, 2014 | 17:22PM EST
  2. Fast Money Halftime Report Final Trade From November 24

    Benzinga | Nov. 24, 2014 | 20:26PM EST
  3. Can Partnering To Fight Hepatitis C Pay At Entanta?

    IBD | Nov. 24, 2014 | 16:44PM EST
  4. Can Partnering To Fight Hepatitis C Pay At Enanta?

    IBD | Nov. 24, 2014 | 16:44PM EST
  5. Dividend Aristocrats In Focus Part 45: AbbVie

    GuruFocus | Nov. 24, 2014 | 16:13PM EST
  6. John Paulson's Top 5 New Holdings For Q3

    GuruFocus | Nov. 21, 2014 | 22:08PM EST
  7. Pharma drugs advance in EU

    IBD | Nov. 21, 2014 | 18:19PM EST
  8. AbbVie, Celgene, Sanofi Drugs Get EU Endorsements

    IBD | Nov. 21, 2014 | 12:28PM EST
  9. Facebook Among New Holdings in Steve Mandel's Portfolio

    GuruFocus | Nov. 20, 2014 | 16:15PM EST
  10. Jeff Auxier Buys Berkshire Hathaway in Third Quarter

    GuruFocus | Nov. 18, 2014 | 16:33PM EST
  11. Five Ethical Drugmakers Keep Leadership Positions

    IBD | Nov. 17, 2014 | 18:27PM EST
  12. Will IPOs WhiteWave, Enanta Surpass Buy Points?

    IBD | Nov. 17, 2014 | 18:27PM EST
  13. Stocks Hitting 52-Week Highs

    Benzinga | Nov. 17, 2014 | 10:18AM EST
  14. Deutsche Bank Initiates Coverage On AbbVie

    Benzinga | Nov. 14, 2014 | 12:08PM EST
  15. Benzinga's Top Initiations

    Benzinga | Nov. 14, 2014 | 09:13AM EST
  16. Deutsche Bank Initiates AbbVie With Buy

    Benzinga | Nov. 14, 2014 | 08:10AM EST
  17. Shire CEO Looks Ahead To Independent Future

    IBD | Nov. 10, 2014 | 16:46PM EST
  18. Merck Down On Hepatitis C Data; Gilead Rises

    IBD | Nov. 10, 2014 | 11:14AM EST
  19. #PreMarket Primer: Monday, November 3: Commercial Space Travel Questioned After Failed Flights

    Benzinga | Nov. 3, 2014 | 07:55AM EST
  20. Humira Lifts AbbVie Earnings

    IBD | Oct. 31, 2014 | 19:03PM EST
  21. Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close At Records High

    Benzinga | Oct. 31, 2014 | 16:54PM EST
  22. AbbVie Beats Q3 Earnings Estimates, Raises Guidance

    IBD | Oct. 31, 2014 | 14:25PM EST
  23. Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal

    IBD | Oct. 31, 2014 | 11:17AM EST
  24. UPDATE: AbbVie Posts Stronger-Than-Expected Q3 Results, Lifts Outlook

    Benzinga | Oct. 31, 2014 | 08:52AM EST
  25. #PreMarket Primer: Friday, October 31: BOJ Spooked By Lackluster Growth And Inflation

    Benzinga | Oct. 31, 2014 | 08:15AM EST
  26. Earnings Scheduled For October 31, 2014

    Benzinga | Oct. 31, 2014 | 05:13AM EST
  27. Amgen Refuses To Split, But Plans Hearten Investors

    IBD | Oct. 28, 2014 | 14:18PM EST
  28. Receptos Soars After Lead Drug Racks Up Another Win

    IBD | Oct. 28, 2014 | 11:46AM EST
  29. Allergan Lifts Guidance; Valeant Suggests Higher Bid

    IBD | Oct. 27, 2014 | 12:17PM EST
  30. My 5 Favorite Stocks With Dividend Growth Of The Week

    GuruFocus | Oct. 27, 2014 | 12:09PM EST
  31. Shire: Who Needs AbbVie?

    IBD | Oct. 24, 2014 | 18:46PM EST
  32. Shire EPS Growth Accelerates, Stock Continues Rebound

    IBD | Oct. 24, 2014 | 11:12AM EST
  33. Gilead's Hep C Dream Drug Faces Demanding Investors

    IBD | Oct. 22, 2014 | 16:44PM EST
  34. Making Money With Charles Payne: 10/20/14

    FoxBusiness | Oct. 21, 2014 | 18:00PM EST
  35. Celgene Reports More Good Crohn's Disease Data

    IBD | Oct. 21, 2014 | 11:32AM EST
  36. #PreMarket Primer: Tuesday, October 21: China's Third Quarter Growth Disappoints

    Benzinga | Oct. 21, 2014 | 07:45AM EST
  37. Must Watch Stocks For October 21, 2014

    Benzinga | Oct. 21, 2014 | 04:04AM EST
  38. AbbVie Unveils $5 Billion Buyback; Blames U.S. For Failed Inversion

    Benzinga | Oct. 20, 2014 | 20:20PM EST
  39. Benzinga's M&A Chatter for Monday October 20, 2014

    Benzinga | Oct. 20, 2014 | 19:27PM EST
  40. ABBVIE

    IBD | Oct. 20, 2014 | 18:57PM EST
  41. Announcement Of Termination Of Proposed AbbVie And Shire Transaction

    Benzinga | Oct. 20, 2014 | 17:13PM EST
  42. Enanta Pharma Reports Update on Collaboration Deal with AbbVie: Will Not Exercise Option for Co-Development, Co. Received $57M Related to Signing, $95M in Milestones

    Benzinga | Oct. 20, 2014 | 16:56PM EST
  43. Celgene's Crohn's Disease Drug Hits Its Marks

    IBD | Oct. 20, 2014 | 11:16AM EST
  44. Benzinga's Weekend M&A Chatter

    Benzinga | Oct. 19, 2014 | 21:58PM EST
  45. UPDATE: Bank Of America Reiterates On AbbVie On Move To Standalone Valuation

    Benzinga | Oct. 17, 2014 | 09:44AM EST
  46. Benzinga's M&A Chatter for Thursday October 16, 2014

    Benzinga | Oct. 17, 2014 | 00:02AM EST
  47. Shire may have to go it alone

    IBD | Oct. 16, 2014 | 18:59PM EST
  48. Shire Can Thrive Without AbbVie, Say Analysts

    IBD | Oct. 16, 2014 | 11:19AM EST
  49. Benzinga's Volume Movers

    Benzinga | Oct. 16, 2014 | 10:36AM EST
  50. Wall Street Drops on Continued Global Concerns

    FoxBusiness | Oct. 16, 2014 | 10:10AM EST
Trading Center